Genmab (GMAB) is down -6.5%, or -$2.14 to $31.03.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GMAB:
- Genmab’s Oncology Advancements and Strategic Positioning Drive Buy Rating
- Genmab announces new data from Phase 1/2 RAINFOL-01 trial
- Genmab Reports Strong Q3 2025 DARZALEX® Sales
- Genmab’s Strong Market Position and Growth Potential Justify Buy Rating with $40 Price Target
- Genmab reports net sales of Darzalex for Q3 2025 of $3.67B